Build status - In Progress

GMCI plus Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC Patients (LuTK02)

GMCI plus Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC Patients (LuTK02)
Recruiting
18 years - 99 years
All
Phase N/A
10 participants needed
1 Location

Brief description of study

This trial is to evaluate the safety and efficacy of adding GMCI to standard of care in patients with stage III/IV NSCLC that are not responding to a first line immune checkpoint inhibitor (ICI).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Non Small Lung Cancer,Non Small Lung Cancer
  • Age: 18 years - 99 years
  • Gender: All

Male or Female 18 years of age or older Non Small Lung cancer

Updated on 04 Aug 2024. Study ID: 844087

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center